Select Your Language: 

As part of our mission, we strive to improve the experience of living with a rare disease by providing support to many organizations that offer crucial programs and services for people living with rare diseases.

The #RAREis Global Advocate Grant was launched in 2022 to provide financial support to advocacy organizations dedicated to advancing the needs of the rare disease community. Since its inception, the program has awarded funding to more than 150 organizations across 20+ countries—fueling efforts to educate, empower and create meaningful change.

In 2025, we will award 25 one-time grants of $5,000 each to rare disease advocacy organizations around the world. These grants are intended to support impactful programs and disease education initiatives.

To be considered, please review the eligibility requirements below and follow the application steps. All applications must be submitted through Amgen’s donation portal by 5 p.m. CT on July 31, 2025. Recipients will be announced in the fall.

Eligibility Requirements

 

To qualify, organizations must meet the following criteria:

  • Focus on serving the rare disease community beyond Amgen’s therapeutic areas.
  • Commit to using the grant funds within the timeframe specified in your application.
  • Not use grant funds to benefit healthcare providers.
  • Submit a signed and dated IRS W-9 form (for U.S. applicants) or W-8 form (for international applicants), dated within the past 12 months.
  • Provide proof of non-profit status:
    • U.S.-based organizations must submit a screenshot from ProPublica confirming 501(c)(3) status.
    • International organizations must provide official documentation or a website screenshot verifying their nonprofit or charitable designation.

Application Process

The #RAREis Global Advocate Grant application involves two steps:

  1. Download and Complete the #RAREis Form
    • Download the #RAREis form here. Be sure to save your progress as you go. Please provide clear, thorough and accurate responses. This information is required in the Amgen donation portal and will be used during the selection process.
      • If English is not your first language, we recommend using a browser with translation capability – like Google Chrome – to assist with navigation
  2.  Submit Through Amgen’s Donation Portal
    • After completing the #RAREis form, please save it on your computer. Ensure the file is clearly labeled with your organization’s name.
    • Then, visit Amgen’s donation portal and create an account (or log in if you already have one).
    • Once logged in, upload the completed #RAREis form, answer the required questions within the portal and provide the required documentation, including:
      • A signed IRS W-9 or W-8 form
      • Proof of nonprofit status
    • When prompted, enter a donation amount of $5,000
  1. Confirm Submission
    • After submitting through Amgen’s portal, you will receive an automated confirmation email. Please keep it for your records.

Disclaimers and Important Notes

  • Amgen cannot issue payments to third-party vendors or intermediaries. Funds must be paid directly to a verified organization via check or direct deposit.
  • A verification process will confirm your organization’s banking and payee information. Inability to verify may result in forfeiture of the #RAREis Global Advocate Grant.
  • Incomplete applications or unanswered questions may disqualify your submission.
  • Past recipients are eligible to reapply for repeat funding.

Questions?

If you have any questions or need support, contact us at rareconnect@amgen.com. We look forward to learning more about your organization’s efforts to make a difference in the rare disease community.

In 2026, the #RAREis Global Advocate Grant program will shift to focus on supporting U.S.-based organizations. We deeply value the passion and contributions of our global advocacy partners and extend our heartfelt thanks for your continued support and understanding as we align our program for future impact.

You are Leaving RAREisCommunity.com

You are now leaving the #RAREis™ Community website. Amgen is not responsible for content or availability of third-party sites.

Return to RAREisCommunity.com OK, Continue X